Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Home
Lindy Vernooij

Lindy Vernooij

PhD Student

Molenaar group

Targeting BCL2 in neuroblastoma

Phone -

Email L.Vernooij-4@prinsesmaximacentrum.nl

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
- jan. 2023
- Thomas F, Eleveld, et al
- Frontiers in Oncology
High-throughput screening identifies idasanutlin as a resensitizing drug for venetoclax-resistant neuroblastoma cells
- jun. 2021
- Lindy, Vernooij, et al
- Molecular Cancer Therapeutics
Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses
- jan. 2021
- Nil A., Schubert, et al
- European Journal of Cancer

View all publications

Lindy Vernooij

Publications

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

High-throughput screening identifies idasanutlin as a resensitizing drug for venetoclax-resistant neuroblastoma cells

Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses